Loic Vincent Sells Shares of Korro Bio, Inc.

Loic Vincent, the Chief Scientific Officer of Korro Bio, Inc. (NasdaqCM: KRRO), sold 3,418 shares of the company on June 16, 2026. The shares were sold at an average price of $10.83, totaling approximately $37,016.94. This transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at Korro Bio, Inc.

Alongside Loic Vincent, other insiders were active on June 16, 2026. Jeffrey Cerio, General Counsel, sold 6,609 shares, while Oliver Dolan, Senior Vice President of Finance, sold 3,383 shares. Todd Chappell, Chief Operating Officer, also sold 3,168 shares. These transactions were executed at an average price of $10.83 per share. Earlier in June, Jean Francois Formela and Timothy Pearson each purchased 14,677 shares on June 10, 2026.

Other Institutional Activity in Korro Bio, Inc.

Several institutional investors have recently adjusted their positions in Korro Bio, Inc. Lynx1 Capital Management LP increased its holdings by 860,381 shares, bringing its total to 1,538,296 shares valued at about $17.4 million. NEA Management Company, LLC added 207,100 shares, ending with 1,297,893 shares worth approximately $14.7 million. Atlas Venture Life Science Advisors, LLC maintained its position at 1,137,149 shares, valued at $12.9 million. Balyasny Asset Management L.P. and Venrock Adviser, LLC both acquired new positions, each holding over 1 million shares worth around $11.7 million and $11.4 million, respectively.

Korro Bio, Inc. Stock Down 14.4%

Shares of Korro Bio, Inc. traded near $10.66. The company has a market capitalization of about $159.4 million. Despite not having a meaningful forward P/E ratio due to its lack of profitability, the stock has a beta of 2.096, indicating higher volatility compared to the market. Korro Bio's 52-week trading range spans from $5.20 to $55.89, with a 50-day moving average of $12.21 and a 200-day moving average of $17.76.

Analysts Set New Price Targets

Analysts have shown interest in Korro Bio, Inc. On May 19, 2026, HC Wainwright & Co. maintained a buy rating with a $15.00 price target. Citigroup initiated coverage on May 18, 2026, also with a buy rating and a $21.00 target. Earlier in the year, Piper Sandler set a high target of $30.00. The consensus among analysts is a buy rating, with an average price target of $20.00 across 10 opinions.

About Korro Bio, Inc.

Korro Bio, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in RNA editing for genetic medicines. Founded in 2018, the company focuses on treating rare and prevalent diseases, including hyperammonemia and conditions like Parkinson's disease. Its RNA editing platform, Oligonucleotide Promoted Editing of RNA, is at the core of its product development. Korro Bio collaborates with Novo Nordisk A/S for cardiometabolic disease treatments and employs 49 people under the leadership of CEO Dr. Ram Aiyar.

Bottom Line

Loic Vincent's recent sale of shares in Korro Bio, Inc. is a notable insider transaction, reflecting ongoing activity among the company's leadership. Investors keep a close eye on such moves, although they don't necessarily indicate a change in the company's outlook. Korro Bio's stock remains volatile, with analysts maintaining positive ratings and setting ambitious price targets, suggesting continued interest in its innovative approach to genetic medicine.